ClinConnect ClinConnect Logo
Search / Trial NCT05285527

MiSight 1 Day Safety Post-Approval Study

Launched by COOPERVISION, INC. · Mar 9, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

The MiSight 1 Day Safety Post-Approval Study is looking to confirm the safety of daily disposable soft contact lenses for children aged 8 to 12 who have myopia, which is a condition where distant objects appear blurry. If your child is between 8 and 12 years old, has a specific level of vision correction need, and is interested in wearing contact lenses for about 10 hours a day, they may be eligible to participate. It’s important that they have glasses they can wear as well.

Participants in this study will wear the MiSight contact lenses while researchers monitor their eye health and comfort. They need to be free from serious eye conditions and infections to ensure safety during the study. The parents or guardians will need to give permission for their child to take part and share some health information. This study is currently recruiting participants, and it’s a great opportunity for children who want to try contact lenses in a safe, supervised environment.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Be between 8 and 12 years of age inclusive at the time of enrollment.
  • 2. Manifest Refraction - Spherical Equivalent Refractive Error (SERE) at baseline between -0.50 D and -7.00 D inclusive (at the corneal plane).
  • 3. Best-corrected visual acuity by manifest refraction of at least 20/25 bilaterally
  • 4. Free of ocular disease or abnormalities (including any corneal scar)
  • 5. The parent/guardian must be capable of comprehending the nature of the study and consent to the use and release of their child's de-identified health care encounter data to be used for purposes of this study. Assent will be obtained from the child in a manner specified by the IRB.
  • 6. Parent/Guardian must sign the Release of Medical Records associated with the outcomes of interest identified from claims data.
  • 7. Interested in wearing contact lenses for approximately 10 hours per day and 6 days per week.
  • 8. Possesses, or obtains prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.
  • Exclusion Criteria:
  • 1. Acute and subacute inflammation or infection of the anterior chamber of the eye.
  • 2. Any eye disease, injury, or abnormality that affects the cornea, conjunctiva, or eyelids.
  • 3. Severe insufficiency of lacrimal secretion (dry eyes).
  • 4. Corneal hypoesthesia (reduced corneal sensitivity), if not aphakic.
  • 5. Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses.
  • 6. Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or use of contact lens solutions.
  • 7. Any active corneal infection (bacterial, fungal, or viral).
  • 8. If eyes are red or irritated.
  • 9. The patient is unable to follow lens handling and wear regimen or unable to obtain assistance to do so.
  • 10. In addition to the labeling contraindications, children who are under medication that would interfere with contact lens wear, or who are using any pharmaceuticals for control of myopia will not be included in the study.

About Coopervision, Inc.

CooperVision, Inc. is a global leader in the contact lens industry, dedicated to advancing the science of vision care through innovative products and clinical research. With a commitment to enhancing the quality of life for millions of wearers worldwide, the company specializes in developing a diverse range of contact lenses, including those for myopia control, astigmatism, and presbyopia. CooperVision actively engages in clinical trials to ensure the safety, efficacy, and comfort of its products, while also contributing to the broader understanding of eye health and vision correction. By fostering partnerships with healthcare professionals and researchers, CooperVision aims to drive advancements in vision care and provide exceptional solutions that meet the evolving needs of eye care practitioners and their patients.

Locations

Milford, Connecticut, United States

Glenview, Illinois, United States

Bellaire, Texas, United States

Danville, California, United States

Fremont, California, United States

Irvine, California, United States

Centennial, Colorado, United States

Saint Johns, Florida, United States

Chicago, Illinois, United States

Morristown, New Jersey, United States

Apex, North Carolina, United States

Chagrin Falls, Ohio, United States

State College, Pennsylvania, United States

Redmond, Washington, United States

Gilbert, Arizona, United States

San Jose, California, United States

Oviedo, Florida, United States

Chicago, Illinois, United States

Carmel, Indiana, United States

Rockville, Maryland, United States

Wellesley, Massachusetts, United States

California, Missouri, United States

Des Peres, Missouri, United States

Bronx, New York, United States

Frisco, Texas, United States

Pleasant Grove, Utah, United States

Sandy, Utah, United States

Morgantown, West Virginia, United States

Beaumont, Texas, United States

San Jose, California, United States

Miami, Florida, United States

Cupertino, California, United States

Dublin, California, United States

Milpitas, California, United States

Oakland, California, United States

Lake Worth, Florida, United States

Pickerington, Ohio, United States

Plano, Texas, United States

Salt Lake City, Utah, United States

Williamsburg, Virginia, United States

San Antonio, Texas, United States

Centerton, Arkansas, United States

Sarasota, Florida, United States

Weston, Florida, United States

Darien, Illinois, United States

Cary, North Carolina, United States

Berkeley, California, United States

Cupertino, California, United States

St. Johns, Florida, United States

Bronx, New York, United States

Corpus Christi, Texas, United States

Markham, Ontario, Canada

Oakville, Ontario, Canada

Patients applied

0 patients applied

Trial Officials

William Gleason, OD

Principal Investigator

Foresight Regulatory Strategies

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials